---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-092360"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2022-04-01T23:59:59+00:00"
generated_at: "2026-06-26T10:30:47.893389+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences enters ATM equity sales agreement for up to $25M

## Summary
- Agreement with Ladenburg Thalmann allows sale of up to $25M common stock; initial prospectus supplement covers $7M.
- Commission of 3.0% of gross proceeds payable to Ladenburg for at-the-market sales.
- Net proceeds to be used for general corporate purposes and funding of clinical programs.
- Company not obligated to sell any shares; sales will be at prevailing market prices.

## SEC filing metadata
- accession: 0001193125-22-092360
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2022-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312522092360/0001193125-22-092360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312522092360/d345612d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-092360
- JSON: https://secwatch.observer/filing/0001193125-22-092360.json
- Plain text: https://secwatch.observer/filing/0001193125-22-092360.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.